Safety and Efficacy of ThisCART22 in Patients With Refractory or Relapsed B Cell Malignancies

B Cell Malignancy Clinical Trial

Official title: A Study to Evaluate the Safety and Clinical Activity of Allogeneic CAR-T Targeting CD22 in Patients With Refractory or Relapsed B Cell Malignancies

Status Recruiting

Clinical Trial Summary

This is a single-center, nonrandomized, open-label, study to evaluate the safety and clinical activity of allogeneic CAR-T targeting CD22 in patients with refractory or relapsed CD22-positive B cell malignancies

Clinical Trial Description

The patients will receive infusion of ThisCART22 cells from health donor ,to evaluate the safety and efficacy of ThisCART22 Cells in patients with refractory or relapsed CD22-positive B cell malignancies.

In this study, the dose range is 0.2-60 x10^6 cells per kg body weight (no more than 3.0 x 10^9 in total). ;

Related Conditions & MeSH terms

• B Cell Malignancy
• Neoplasms

• NCT number: NCT04601181
• Study type: Interventional
• Source: Fundamenta Therapeutics, Ltd.
• Contact: Xingbing Wang, M.D.
• Phone: +8613856007984
• Email: wangxingbing@ustc.edu.cn
• Status: Recruiting
• Phase: Phase 1
• Start date: October 23, 2020
• Completion date: October 15, 2023